Cargando…

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations

Objective: A comparative analysis was performed to investigate the potential risk factors of Adverse Events Following Immunization (AEFI) after receiving different booster vaccines. Methods: From 18 January 2021 to 21 January 2022, the Health Care Workers (HCWs) of Guizhou Provincial Staff Hospital...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Yunhua, Wang, Yan, Liu, Jian, Zha, Yan, Yang, Yuqi, Li, Ni, Zhou, Yalin, Zhu, Jinli, Roberts, Neil, Liu, Lin, Li, Yaying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696033/ https://www.ncbi.nlm.nih.gov/pubmed/36366377 http://dx.doi.org/10.3390/vaccines10111869

Ejemplares similares

Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China
por: Wei, Yunhua, et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2022)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

AEs after homologous versus heterologous COVID-19 booster
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Uptake of Heterologous or Homologous COVID-19 Booster Dose and Related Adverse Events Among Diabetic Patients: A Multicenter Cross-Sectional Study — China, 2022
por: Zhang, Fan, et al.
Publicado: (2023)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
por: Honfi, Dániel, et al.
Publicado: (2022)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination
por: Vadrevu, Krishna Mohan
Publicado: (2023)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster – authors' reply
por: Rose, Winsley, et al.
Publicado: (2023)

Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia
por: Soegiarto, Gatot, et al.
Publicado: (2023)

Comparing the SARS-CoV-2-specific antibody response in human milk after homologous and heterologous booster vaccinations
por: Mulleners, Sien J., et al.
Publicado: (2023)

Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study
por: Flores-Lastra, Nancy, et al.
Publicado: (2023)

Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel
por: Park, Sungsoo, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2023)

(99m)Tc-methylene diphosphonate SPECT/CT imaging of gout spondylitis: a case report
por: Wang, Yan, et al.
Publicado: (2022)

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
por: Jara, Alejandro, et al.
Publicado: (2022)

Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants
por: Buathong, Rome, et al.
Publicado: (2022)

Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients
por: Gaete-Argel, Aracelly, et al.
Publicado: (2023)

Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study
por: Wen, Gui-Ping, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
por: Atmar, Robert L., et al.
Publicado: (2021)

ACTION ON FIBROBLASTS OF EXTRACTS OF HOMOLOGOUS AND HETEROLOGOUS TISSUES
por: Carrel, Alexis, et al.
Publicado: (1923)

μ-Opioid receptor desensitization: homologous or heterologous?
por: Llorente, Javier, et al.
Publicado: (2012)

Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil
por: Marra, Alexandre R., et al.
Publicado: (2023)

Antibody Response to COVID-19 Vaccines in Healthcare Workers: Which One is More Successful? Homologous or Heterologous?
por: Karakoc, Zehra Cagla, et al.
Publicado: (2023)

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older
por: Tamburro, Manuela, et al.
Publicado: (2022)

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
por: Mrak, Daniel, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events
por: Liu, Xinyu, et al.
Publicado: (2023)

Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling
por: Ai, Jingwen, et al.
Publicado: (2022)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rhc3j8ti4abhkcu6h9gohpnb2p